Zimmer Biomet

Zimmer Biomet to Present at the 2023 Wells Fargo Healthcare Conference

Retrieved on: 
Wednesday, August 23, 2023
Conference, NYSE, Zimmer Biomet, Rare-earth element, Broadcasting, Pharmaceutical industry

WARSAW, Ind., Aug. 23, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 9:30 a.m. ET (6:30 a.m. PT).

Key Points: 
  • WARSAW, Ind., Aug. 23, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 9:30 a.m.
  • ET (6:30 a.m. PT).
  • A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com .
  • The webcast will be archived for replay following the conference.

Bryan Hanson Named CEO of 3M's Health Care Business Group

Retrieved on: 
Tuesday, August 22, 2023
Minimally invasive procedure, Walgreens Boots Alliance, Massachusetts College of Liberal Arts, Medical device, Senior, Pharmacia, Surgery, Information technology, Zimmer Biomet, Culture, Schering-Plough, Women's Health Care Nurse Practitioner-Board Certified, Roman, Pharmacia & Upjohn, Bristol Myers Squibb, Sale, Cox, Cardinal Health, Patient, Health care, Texas Instruments, Outline of health sciences, Seattle Mariners, Growth, Medtech, NYSE, Management, Pharmaceutical industry, Nursing, AmeriCares, Medtronic, Novartis, Covidien

Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.

Key Points: 
  • Hanson will join 3M on Sept. 1 as CEO of the Health Care Business Group.
  • 3M's Health Care Business Group, with $8.4 billion in sales in 2022, is a diversified health care technology leader with a deep and diverse portfolio of trusted brands, global capabilities, and leadership in attractive end market segments such as wound care, oral care, health care IT, and biopharma filtration.
  • As a standalone business, Health Care will be well-positioned to deliver industry-leading innovation that enables better, smarter, and safer health care for patients worldwide.
  • "I am honored and excited to join 3M's Health Care Business Group at such an important time in its evolution," said Hanson.

Zimmer Biomet Announces Leadership Transition

Retrieved on: 
Tuesday, August 22, 2023
Lead, Suki Schorer, Operation, Business development, International, Medical image sharing, Zimmer Biomet, Fusion Global Business Solutions, Culture, EVP, ZB, Bard (company), Baxter International, Becton, Dickinson and Company headquarters, Patient, CFO, Growth, Johnson & Johnson, NYSE, Dental, Worldwide, Management, Orthopedic surgery, Finance, List of characters in Ramayana

WARSAW, Ind., Aug. 22, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served as the Company's President and CEO since late 2017 and Chairman since 2021, and is departing to take on another CEO role.

Key Points: 
  • Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021.
  • Mr. Tornos joined Zimmer Biomet in November 2018 as Group President, Orthopedics and a year later was named Group President, Global Businesses and the Americas.
  • His deep expertise in the medtech sector, commercial prowess and proven leadership experience make him the ideal leader for Zimmer Biomet as we move into our next phase of innovation and growth," said Mr. Begley.
  • During his tenure at Zimmer Biomet, he spearheaded the Company's transformation, reshaping the mission, culture, corporate strategy, quality, compliance, operations and market performance.

Verily Appoints Laura O’Donnell as General Counsel

Retrieved on: 
Wednesday, June 28, 2023
Professional Services, Data Management, Health, Technology, Legal, Health Technology, General Health, General Electric, GE HealthCare, General counsel, Zimmer Biomet, McKesson Corporation, COVID-19, GE, Private practice, Privacy, Government, Drug Quality and Security Act, Growth, Faegre & Benson, Audit

Verily , an Alphabet precision health technology company, today announced the appointment of Laura O’Donnell as General Counsel.

Key Points: 
  • Verily , an Alphabet precision health technology company, today announced the appointment of Laura O’Donnell as General Counsel.
  • Laura has led a distinguished legal and compliance career in the healthcare industry globally for more than two decades.
  • Prior to McKesson, Laura had multiple roles in GE Healthcare’s legal department which culminated in a promotion to Officer of General Electric and General Counsel of GE Healthcare.
  • As General Counsel, Laura had responsibility for legal, compliance, clinical research, privacy and other functions across 120 countries.

Patient Square Announces Addition of Medical Technology Executive Ellie Humphrey to Transformation and Growth Team

Retrieved on: 
Wednesday, June 14, 2023
Transformation, University, Zimmer Biomet, Business, University of Virginia Darden School of Business, Harvard College, McKinsey & Company, Government, Operation, Medtronic, Growth, SVP, Virginia School for Girls, Nursing, Management

MENLO PARK, Calif., June 14, 2023 /PRNewswire/ -- Patient Square Capital ("Patient Square"), a leading health care investment firm, announced today the appointment of Ellie Humphrey as Operating Executive on Patient Square's Transformation and Growth Team.

Key Points: 
  • MENLO PARK, Calif., June 14, 2023 /PRNewswire/ -- Patient Square Capital ("Patient Square"), a leading health care investment firm, announced today the appointment of Ellie Humphrey as Operating Executive on Patient Square's Transformation and Growth Team.
  • Ms. Humphrey brings over 20 years of experience driving growth and operational excellence in health care companies.
  • We believe she will be a tremendous asset to Patient Square and to our portfolio companies," said Karr Narula, Founding Partner and Head of the Transformation and Growth Team at Patient Square.
  • Prior to Patient Square, Ms. Humphrey served in senior leadership roles in global health care companies, most recently at Zimmer Biomet as SVP and Chief Transformation Officer.

NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Mayo, Chronic pain, Spinal cord stimulator, Mayo Clinic, Surgeon, On Formally Undecidable Propositions of Principia Mathematica and Related Systems, Zimmer Biomet, Stereoelectroencephalography, Spinal cord, Calendar, DSM-IV codes, Low back pain, Neurosurgery, ROSA, Research and development, NMTC, Development, Congress of Neurological Surgeons, Brain, American Association of Neurological Surgeons, AANS, Patient, Patent, Investment, Administration, EDEN, Research, FDA, SCS, Medical device, Management, Cryptocurrency, Operation, Evo

Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.

Key Points: 
  • Product revenue was $466,000 in the fiscal second quarter 2023, compared to product revenue of $37,000 in the fiscal second quarter 2022.
  • Total operating expenses in the fiscal second quarter 2023 were $3.5 million, compared with $3.0 million in the same period of the prior fiscal year.
  • Research and Development expense in the fiscal second quarter 2023 was $1.7 million compared with $1.2 million in the same period of fiscal 2022.
  • Net loss was $3.5 million for the fiscal second quarter 2023, compared to a net loss of $3.1 million in the prior year period.

Global Disposable Hospital Supplies Market to Grow by $21.49 Billion During 2023-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 8, 2023
Hospitals, Health, Medical Supplies, Zimmer Biomet, Medline Industries, Smith, Research, BD (company), Cardinal Health, Fresenius Medical Care, Maharashtra University of Health Sciences, 3M, Ambu (company), Boston Scientific, Thermo Fisher Scientific, Edel SE & Co. KGaA, Stryker Corporation, Teleflex, Medtronic, Retail

This study identifies the technological advances in the healthcare industry as one of the prime reasons driving the disposable hospital supplies market growth during the next few years.

Key Points: 
  • This study identifies the technological advances in the healthcare industry as one of the prime reasons driving the disposable hospital supplies market growth during the next few years.
  • Also, rising demand for distribution through online channels and retailers and high growth potential in emerging economies will lead to sizable demand in the market.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
  • The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Zimmer Biomet to Present at Bank of America Securities and Jefferies Healthcare Conferences

Retrieved on: 
Thursday, April 27, 2023
Bank, NYSE, Conference, Zimmer Biomet, Pharmaceutical industry

WARSAW, Ind., April 27, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at two upcoming healthcare conferences.

Key Points: 
  • WARSAW, Ind., April 27, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at two upcoming healthcare conferences.
  • The team will be presenting at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 1:40 p.m.
  • Additionally, members of the management team will be presenting at the Jefferies Healthcare Conference on Wednesday, June 7, 2023.
  • A live webcast of the presentations can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com .

Hyaluronic Acid Market Size Worth USD 19.87 Billion in 2032 | Emergen Research

Retrieved on: 
Tuesday, March 7, 2023
Hyaluronic acid, IgG4-related ophthalmic disease, Skin, Prevalence, Roche, Acquisition, News, Research, Elastin, Skin care, Growth, HA, USD, Kikkoman, AMD, Tissue, Arthropathy, Elective surgery, Niece and nephew, Arthritis, Eye, Zimmer Biomet, Osteoarthritis, Dietary supplement, Joint, Pain, Ophthalmology, Inflammation, Collagen, Ageing, Cosmetics, Pharmaceutical industry, Allergan

VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.

Key Points: 
  • VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.
  • The increasing awareness about the health benefits of hyaluronic acid and its widespread use in the cosmetics and healthcare industry are some of the primary factors driving the growth of the hyaluronic acid market.
  • Hyaluronic acid is used in various cosmetic products, including anti-aging creams, moisturizers, and serums, to hydrate and rejuvenate the skin.
  • One of the major factors driving the growth of the hyaluronic acid market is the increasing demand for anti-aging products.

Hyaluronic Acid Market Size Worth USD 19.87 Billion in 2032 | Emergen Research

Retrieved on: 
Tuesday, March 7, 2023
Hyaluronic acid, IgG4-related ophthalmic disease, Skin, Prevalence, Roche, Acquisition, News, Research, Elastin, Skin care, Growth, HA, USD, Kikkoman, AMD, Tissue, Arthropathy, Elective surgery, Niece and nephew, Arthritis, Eye, Zimmer Biomet, Osteoarthritis, Dietary supplement, Joint, Pain, Ophthalmology, Inflammation, Collagen, Ageing, Cosmetics, Pharmaceutical industry, Allergan

VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.

Key Points: 
  • VANCOUVER, B.C., March 7, 2023 /PRNewswire/ -- The global Hyaluronic Acid market size was valued at USD 9.56 Billion in 2022 and is expected to reach valuation of USD 19.87 Billion in 2032 growing at a CAGR of 7.5% during the forecast period, according to a recent report by Emergen Research.
  • The increasing awareness about the health benefits of hyaluronic acid and its widespread use in the cosmetics and healthcare industry are some of the primary factors driving the growth of the hyaluronic acid market.
  • Hyaluronic acid is used in various cosmetic products, including anti-aging creams, moisturizers, and serums, to hydrate and rejuvenate the skin.
  • One of the major factors driving the growth of the hyaluronic acid market is the increasing demand for anti-aging products.